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Abstract
Background—Younger women (aged 18–44 years) diagnosed with breast cancer often face 
more aggressive tumors, higher treatment intensity, and lower survival rates than older women. In 
this study, we estimated incident breast cancer costs by stage at diagnosis and by race for younger 
women enrolled in Medicaid.
Methods—We analyzed cancer registry data linked to Medicaid claims in North Carolina from 
2003 to 2008. We used Surveillance, Epidemiology, and End Results (SEER) Summary 2000 
definitions for cancer stage. We split breast cancer patients into two cohorts: a younger and older 
group aged 18–44 and 45–64 years, respectively. We conducted a many-to-one match between 
patients with and without breast cancer using age, county, race, and Charlson Comorbidity Index. 
We calculated mean excess total cost of care between breast cancer and non-breast cancer patients.
Results—At diagnosis, younger women had a higher proportion of regional cancers than older 
women (49 vs. 42%) and lower proportions of localized cancers (44 vs. 50%) and distant cancers 
(7 vs. 9%). The excess costs of breast cancer (all stages) for younger and older women at 6 months 
after diagnosis were $37,114 [95% confidence interval (CI) = $35,769–38,459] and $28,026 (95% 
CI = $27,223–28,829), respectively. In the 6 months after diagnosis, the estimated excess cost was 
significantly higher to treat localized and regional cancer among younger women than among 
older women. There were no statistically significant differences in excess costs of breast cancer by 
race, but differences in treatment modality were present among younger Medicaid beneficiaries.
Conclusions—Younger breast cancer patients not only had a higher prevalence of late-stage 
cancer than older women, but also had higher within-stage excess costs.
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Introduction
Over 22,000 women younger than 45 years of age (henceforth ‘‘younger women’’) were 
diagnosed with breast cancer in 2013 in the United States, approximately 11% of new breast 
cancer cases [1]. Breast cancer in younger women typically has higher risk biologic features, 
is diagnosed at a more advanced stage, and has poorer survival rates compared to breast 
cancer among older women [2, 3]. As a result of these differences in tumor types between 
younger and older women, younger women may also have more intense or aggressive 
treatments and have distinct and more prevalent side effects from treatment than older 
women [2, 4–6]. These side effects can include quality of life impacts, fertility problems, 
depression [6–9], and generate substantial productivity losses [10–12].
Health and economic outcomes may be worse among younger women of color and younger 
women enrolled in Medicaid. Medicaid beneficiaries and minorities of all ages are more 
likely to present with advanced stage cancers [2, 13–19], and are less likely to receive 
recommended treatments [20, 21], Even within Medicaid, racial/ethnic disparities exist in 
screening [22], incidence [23], and quality of care [20, 24]. Because Medicaid status is 
associated with health disparities for breast cancer patients, the Medicaid population could 
be an important group to assess potential differences between younger and older women 
with breast cancer.
Few studies have examined the costs of breast cancer treatment in a Medicaid population 
[18, 25–29]. One study of the costs of breast cancer treatment among younger women in 
Medicaid used a cross-sectional, prevalence-based design [11]. Prevalent or annual costs 
provide a view of costs for a cross-section of women across the spectrum of the treatment 
continuum. A different approach would involve using incident costs, which provide cost 
estimates from the onset of disease until the end of the disease or for a specific period of 
time, typically a year [30]. For cancer, incident cost estimates provide more information 
about the value of preventing disease. We are not aware of any studies that report incident 
medical costs of breast cancer treatment by stage at diagnosis among younger women 
insured by Medicaid.
Our study fills this gap by estimating incident breast cancer treatment costs by age at 
diagnosis and by race/ethnicity for women under age 45 years versus those 45–64 years 
enrolled in Medicaid in North Carolina. We also investigated whether the treatment costs are 
associated with a later stage of diagnosis. Providing estimates by stage is critical because in 
postmenopausal women, stage at diagnosis has been shown to substantially influence 
treatment costs [31].
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Methods
Data
We analyzed 2003–2008 North Carolina Central Cancer Registry data linked to Medicaid 
enrollment files for the same time period, the most recent linked data available at the time of 
the analysis. The data were maintained by the Integrated Cancer Information and 
Surveillance System at the University of North Carolina and covered 100% of the North 
Carolina Medicaid population [31, 32]. The Institutional Review Boards at RTI International 
and University of North Carolina approved the research plan for this study.
The cancer registry file contains demographic characteristics including race; county; primary 
cancer site; cancer staging using the Surveillance, Epidemiology, and End Results (SEER) 
Summary 2000 definitions; date of diagnosis; and date of death. The Medicaid data include 
the following data files: enrollment, inpatient hospital, long-term care, other non-
institutional, and prescription drug. The enrollment data file contains monthly indicators of 
Medicaid enrollment status, demographics, and the cancer registry link identifier.
Cost Estimation
We included women who were diagnosed with invasive primary breast cancer in the North 
Carolina Central Cancer Registry between ages 18 and 64 years (Table 1). We excluded 
those with benign tumors, those not enrolled in Medicaid at diagnosis, and those who died 
within 9 months of diagnosis so we could observe a minimum of 3 months of cancer claims 
data while allowing for a 6-month buffer for end-of-life costs.
We included breast cancer patients in our analysis only if the patients were continuously 
enrolled in each of the follow-up periods analyzed (3, 6, and 12 months), known as the 
initial phase of care (Table 1) [33]. We defined continuous enrollment separately for each 
time period as having either a fee-for-service only (FFS) or a primary case management only 
(PCCM) plan in Medicaid in consecutive months. We included women with FFS because we 
could obtain all medical costs associated with a patient’s treatment since providers are paid 
by service provided, as opposed to a managed care plan where Medicaid pays a monthly 
capitation payment for each enrollee [34]. We further included women with PCCM plans 
because during our analysis time period, providers of PCCM patients were paid on a fee-for-
service model [35]. In addition to our younger cohort of women with breast cancer, we also 
estimated costs at 6 months for a cohort of women aged 45–64 years. We followed all the 
same sample restrictions as for the younger women with breast cancer. These women were 
analyzed to provide a comparison to younger women with breast cancer.
We calculated costs for two groups of breast cancer patients (aged 18–44 years and aged 45–
64 years) and two comparison groups of female, non-breast cancer patients aged 18–44 
years and aged 45–64 years who were enrolled for at least 1 month in a FFS only or PCCM 
only plan in Medicaid between 2003 and 2008. Due to sample size limitations, we did not 
require the non-breast cancer population to be continuously enrolled. We excluded all 
patients in the non-breast cancer population who died while enrolled in Medicaid and who 
had inconsistent birth date information across enrollment years.
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We conducted a coarsened exact match between the breast cancer patients and patients 
without breast cancer using categorical 5-year birth year groups (1960–1964, 1965–1969, 
1970–1974, 1975–1979, 1980–1984, 1985–1989), county, race (white, black, other), and a 
Charlson Comorbidity Index (CCI; zero, greater than [36]. We estimated the CCI using data 
from the 3 months after breast cancer diagnosis because requiring cancer patients to be 
continuously enrolled pre-diagnosis greatly reduced sample sizes. We excluded cancer from 
the [37]. We retained all matches and used weights to control for the varying number of non-
breast cancer patients cancer case [38].
We first estimated average monthly total Medicaid insurance medical payments for three 
follow-up periods 6, and 12 months from diagnosis) using linear regression. For each 
follow-up period, we estimated separate regressions for younger women of all races and by 
race younger women. Each regression included indicators SEER stage at diagnosis, number 
of months enrolled, year indicators. We then estimated the total Medicaid insurance medical 
payments for each follow-up period multiplying the number of months in the follow-up 
period by the estimated per-month payment for that follow-up period. In addition, we 
estimated monthly and total for one follow-up period (6 months from diagnosis) older 
women with and without breast cancer. We calculated excess costs as the difference in mean 
total payments between the patients with and without breast cancer stage. We also calculated 
95% confidence intervals All costs were adjusted to 2014 dollars using a domestic product 
deflator [39].
Treatment prevalence
Using the same analytic sample as in the cost estimation, we calculated the prevalence of the 
following treatments age group, race (white and black), and follow-up period and 12 
months): surgery (mastectomy or breast conserving), reconstruction, chemotherapy, and 
radiotherapy. defined the treatment categories following the method KE Reeder-Hayes, AM 
Meyer, SB Dusetzina, H Liu SB Wheeler [40]. All estimates were generated using 13.1 
(College Station, TX).
Results
Table 2 compares the age categories, CCI, cancer stages, and race of younger compared to 
older breast cancer patients. Due to the coarsened exact matching, the cancer and non-cancer 
samples for younger and older women match exactly on the variables in Table 2. On 
average, younger breast cancer patients were diagnosed at age 39 years, whereas older 
patients were diagnosed at age 55 years. Overall, 89 and 79% of younger and older women, 
respectively, had a CCI of zero in the 3 months after their cancer diagnosis, excluding their 
cancer. For younger women, at 6 months, regional cancer was the most common stage at 
diagnosis (49%), followed by localized cancer (44%). On the other hand, older women had a 
higher percentage of localized cancer (50%) and lower percentage of regional (42%).
Medicaid costs were significantly higher among younger women with breast cancer than 
those without breast cancer for all stages and follow-up periods (Table 3). The excess costs, 
relative to no cancer, at 6 months after diagnosis were $37,114 [confidence interval (CI) = 
$35,769–38,459]. Excess costs at 6 months increased with cancer stage for localized, 
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regional, and distant cancer stages at 6 months, respectively. There were no statistically 
significant differences in excess costs of breast cancer by race among younger Medicaid 
beneficiaries.
In the older population, the estimated excess cost of $28,026 (CI = $27,223–28,829) at 6 
months was significantly higher among older women with breast cancer compared to those 
without breast cancer. Similar to the younger women, the excess costs of breast cancer 
increased with each stage. In the 6 months after diagnosis, the estimated excess cost was 
significantly higher to treat localized and regional cancer among younger women with breast 
cancer compared to older women.
Table 4 presents the prevalence of the following treatment categories by age at diagnosis and 
race: surgery, reconstruction, chemotherapy, and radiotherapy. For the full sample, the 
prevalence of all treatment categories except radiotherapy at 6 months was higher for 
younger women than for older women. The same pattern was also evident for white women. 
Among black women, the rates of chemotherapy treatment were higher among younger 
women. In addition, the rates of surgery and reconstruction were higher for white women 
compared to black women, especially among younger women.
Figure 1 presents mean monthly medical costs incurred by breast cancer patients for each 
stage at diagnosis. The overall pattern in average monthly costs is similar among each stage: 
highest costs during the first 6 months and then a downward trend that tapers off around 12 
months. Generally, costs that occur after the first 12 months of care are known as 
‘‘continuing’’ phase of care [41]. Breast cancer patients with distant stage maintain a 
consistently higher average monthly cost than patients with localized or regional breast 
cancer. Monthly costs from distant stage are highest at 4 months after diagnosis at around 
$12,000. Monthly costs from localized or regional stage converge closely 3–4 months after 
diagnosis at $6000 but diverge as monthly costs from regional stage continue to increase 
while monthly costs from localized stage begin to decrease.
Discussion
Our study has four main findings. First, younger breast cancer patients had a higher 
prevalence of late-stage breast cancer than older women in Medicaid. Second, younger 
breast cancer patients in Medicaid had higher total breast cancer attributable costs than older 
Medicaid beneficiaries with breast cancer. Third, younger women had higher within-stage 
breast cancer costs. Fourth, we did not find statistically significant differences in excess 
costs by race, but black women with breast cancer were less likely to receive surgery or 
reconstruction in the first 12 months after diagnosis.
The first three findings suggest that the excess cost of breast cancer in younger women is not 
solely due to later stage diagnosis. The difference in breast cancer treatment costs by stage at 
diagnosis has been reported in prior studies; [18, 31, 42] however, these costs have not been 
estimated for younger women. For example, Subramanian et al. [18] conducted a study on 
treatment cost for breast cancer patients enrolled in Medicaid in North Carolina and 
estimated that the incremental costs at 24 months after diagnosis were $22,343, $41,005, and 
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$117,033 for those with localized, regional, and distant breast cancers, respectively [18]. 
Khanna et al. [27] found that for a woman with breast cancer in the 2005 West Virginia 
Medicaid population, fee-for-service all-cause healthcare costs were $3321 significantly 
higher than women without breast cancer [43].
One of the key strengths of this study is the linkage of administrative and cancer registry 
data to estimate costs for younger and older women diagnosed with breast cancer in a 
Medicaid population. We were able to capture incident breast cancer costs occurring from 
the date of diagnosis, as opposed to either a reliance on an algorithm to detect the stage at 
diagnosis [31] or prevalence-based costs [10, 11]. Another strength of using cancer registry 
data by stage at diagnosis is the ability to examine whether costs for younger women were 
higher as a result of a late stage at diagnosis. Finally, we leveraged the size of our claims 
data to construct two separate comparisons for younger women: a sample of women without 
breast cancer used to estimate the attributable costs; and a sample of older women diagnosed 
with breast cancer used to compare costs.
Our results showed no significant differences in incident costs by race among younger 
Medicaid beneficiaries. However, this does not imply that black and white women received 
similar treatments. In fact, black women were less likely to receive surgery and 
reconstruction. It may be that black women are more likely to receive less expensive 
procedures (e.g., mastectomy without reconstruction) but be more likely to have costly 
treatment complications, making the total cost equivalent.
In comparison, an earlier study found significant racial/ethnic differences in prevalent costs 
nationally among younger Medicaid beneficiaries [11]. Differences in excess breast cancer 
costs could be caused by differences in access to quality survivorship care, coordination of 
care, or in patient characteristics including health status and socioeconomic differences [44, 
45] It is possible that our continuous enrollment exclusions hid underlying racial/ethnic 
differences in incident costs. However, we did not detect differences in incident costs across 
races/ethnicities at any of the continuous enrollment periods analyzed (3, 6, and 12 months). 
This study’s results suggest that differences in observed racial/ethnic disparities across the 
two studies may not be attributable to initial treatment costs.
This study has several limitations. First, we only analyzed data from Medicaid in one state; 
therefore, the findings reported here may not be reflective of the treatments or resources 
used in other settings. Second, we could not account for unobserved differences between the 
cohorts. The encounter data may not have captured all diagnoses included in the CCI, which 
had to be calculated after breast cancer diagnosis. There is also substantial heterogeneity in 
tumor biology within the SEER cancer stages used in the analysis. Third, although our cost 
measure included all Medicaid payments, including those from adverse events following 
treatment [46], other facets of the economic burden of breast cancer for younger Medicaid 
beneficiaries were not included. These include the time cost of seeking care, lost 
productivity, and changes to health-related quality of life [11]. Fourth, our analysis was 
focused on Medicaid fee-for-service; Medicaid managed care was excluded. Fifth, sample 
sizes prevented us from extending the follow-up period past 12 months, which limited our 
ability to detect treatments occurring later such as reconstruction following radio-therapy. 
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Therefore, the estimated treatment costs may be underreported. Despite these limitations, 
this study offers an important contribution to the literature on the incidence-based cost of 
breast cancer treatment for younger Medicaid beneficiaries by stage at diagnosis. Incidence-
based cost estimates provide information about the treatment phase for cancer, where 
prevalence-based costing provides a cross-section of patients along the treatment spectrum. 
Incidence-based costs are also critical for future research as inputs into cost-effectiveness 
analyses for decision making [30].
Clinical care for breast cancer has continued to evolve since the years included in this 
analysis. Costs for cancer care in general have increased faster than overall inflation. New 
cellular targets have been identified in breast cancer, and novel targeted therapies have 
contributed significantly to rising treatment costs. If, as with the treatments studied here, 
oncologists use these new treatments more intensively among younger women, it could 
increase the estimated gap between costs across the age groups.
The findings from this study have several implications. Women whose breast cancer was 
detected through the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP) can enroll in Medicaid to cover their treatment. Studies have shown that 
women using the NBCCEDP have an earlier stage at detection, shorter treatment delays, and 
survival benefits compared to similar women who do not receive services through 
NBCCEDP. [47] CDC conducts educational campaigns to help younger women understand 
their risk for breast cancer and catch cancers at earlier stages, as part of initiatives funded 
through the Education and Awareness Requires Learning Young (EARLY) Act [48]. For 
example, digital media campaigns such as Bring Your Brave inspire young women who may 
be at high risk to learn their own risk for breast cancer and talk with their health care 
provider about their risk. Bring Your Brave has an opportunity to reach all women, 
regardless of socioeconomic status or race, to increase awareness about risk.
As the Medicaid program continues to evolve, the treatment cost estimates reported in this 
paper could inform decisions for treating invasive breast cancer in the Medicaid population. 
Further, these treatment cost estimates could be used in modeling interventions to estimate 
the cost-effectiveness of invasive breast cancer treatment in women enrolled in Medicaid. 
The estimates may also be helpful for economic evaluations of multifaceted prevention 
strategies among younger women.
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See Table 5.
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Fig. 1. 
Adjusted average monthly cost per person from month of diagnosis to 12 months for 
Medicaid beneficiaries aged 18–44 years by SEER stage of diagnosis
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Table 1
Sample selection criteria by age at diagnosis
Inclusion criteria
Younger women (aged 18–44) Older women (aged 45–64)
Sample size Number dropped Sample size Number dropped
Women diagnosed with breast cancer in age category 1135 2717
Non-benign tumor 1019 116 2337 380
Enrolled in Medicaid at diagnosis 877 142 2028 309
Survived at least 9 months post-diagnosis 844 33 1898 130
Continuously enrolled at least 3 months post-diagnosis 520 324 - -
Continuously enrolled at least 6 months post-diagnosis 456 64 1264 634
Continuously enrolled at least 12 months post-diagnosis 337 119 - -
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Table 2
Characteristics of women diagnosed with breast cancer by age at diagnosis
Variable
Women aged 18–44 years at diagnosis
Women aged 45–64 years 
at diagnosis Continuously 
enrolled 6 months from 
diagnosis (N = 1177)
Continuously enrolled 3 
months from diagnosis 
(N = 520)
Continuously enrolled 6 
months from diagnosis 
(N = 456)
Continuously 
enrolled 12 months 
from diagnosis (N = 
337)
Age (year)a 38.54 38.48 38.39 54.62
Birth year
 1955–1959 1% 1% 1%
 1960–1964 38% 39% 43% -
 1965–1969 35% 34% 31% -
 1970–1974 18% 17% 16% -
 1975–1979 6% 6% 6% -
 1980–1984 2% 2% 2% -
 1985–1989 0.4% 0.4% 0.6% -
Charlson comorbidity index (CCI)
 CCI score = 0 89% 90% 89% 79%
 CCI score >0 11% 10% 11% 21%
Surveillance, epidemiology, and end results (seer) stage at diagnosis
 Localized 44% 44% 45% 50%
 Regional 48% 49% 48% 42%
 Distant 8% 7% 7% 9%
Race
 White 48% 48% 46% 49%
 Black 46% 46% 47% 40%
 Other 7% 6% 7% 10%
No. of matched 
comparisons 211,022 190,211 158,945 121,106
aWe matched using birth year intervals; however, we present age in this table for further information
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Table 3
6-month excess costs for Medicaid beneficiaries with breast cancer, by SEER stage, age at diagnosis and race
Aged 18–44 years Aged 45–64 years
Full sample
 All stages $37,114a $28,026a,b
($35,769; $38,459; N = 456) ($27,223; $28,829; N = 1,117)
 Localized $30,036a $18,055a,b
($28,504; $31,568; N = 200) ($17,269; $18,842; N = 586)
 Regional $36,533a $27,107a,b
($35,207; $37,860; N = 222) ($26,110; $28,105; N = 489)
 Distant $44,659a $38,872a
($40,653; $48,664; N = 34) ($36,418; $41,326; N = 102)
White women
 All stages $36,905a $29,620a,b
($35,034; $38,755; N = 217) ($28,452; $30,787; N = 579)
 Localized $29,100a $17,978a,b
($27,186; $31,013; N = 102) ($16,843; $19,114; N = 301)
 Regional $34,226a $28,923a,b
($32,245; $36,207; N = 99) ($27,445; $30,401; N = 228)
 Distant $47,292a $41,748a
($41,410; $53,174; N = 16) ($38,149; $45,347; N = 50)
Black women
 All stages $36,873a $27,292a,b
($34,863; $38,883; N = 210) ($26,146; $28,438; N = 476)
 Localized $30,847a $18,667a,b
($34,903; $38,535; N = 83) ($17,448; $19,887; N = 227)
 Regional $36,719a $26,384a,b
($34,903; $38,535; N = 111) ($25,062; $27,706; N = 206)
 Distant $42,642a $36,900a
($36,749; $48,535; N = 16) ($33,284; $40,515; N = 43)
a
Excess cost is significantly different among breast cancer and comparison samples at the 1% level 95% confidence intervals in parentheses
bSignificantly different from women aged 18–44 years at the 1% level
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Table 4
Treatment prevalence among Medicaid beneficiaries with breast cancer, by age at diagnosis and race
Aged 18–44 years Aged 45–64 years
6 months 12 months 6 months 12 months
% % % %
Surgery: mastectomy or breast conserving 62.5 77.4 55.1a 68.0a
Reconstruction (among women with surgery) 6.8 (10.9) 9.2 (11.9) 2.5a (4.2) 3.3a (4.7a)
Chemotherapy 45.6 53.4 28.9a 37.2a
Radiotherapy 9.0 55.2 11.6 43.3a
White women
 Surgery: mastectomy or breast conserving 68.7 81.9 57.9a 70.1a
 Reconstruction 11.1 (16.1) 16.1 (19.7) 2.9a (4.8a) 4.1a (5.5a)
 (among women with surgery)
 Chemotherapy 45.6 52.3 30.7a 38.8a
 Radiotherapy 9.2 58.7 13.6 45.9a
Black women
 Surgery: mastectomy or breast conserving 55.2 70.9 51.9 66.1
 Reconstruction 3.3 (6.0) 3.8 (5.4) 1.7 (3.2) 2.5 (3.7)
 (among women with surgery)
 Chemotherapy 45.2 54.4 28.6a 37.2a
 Radiotherapy 9.0 51.3 9.5 41.4
aSignificantly different from women aged 18–44 years at the 1% level
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Table 5
Twelve-month excess costs for Medicaid beneficiaries with breast cancer, by SEER stage, and age at diagnosis
Aged 18–44 years Aged 45–64 years
Full sample
(N = 337) (N = 868)
All stages $66,596a $45,914a,b
($63,551; $69,641) ($44,231; $47,598)
Localized $46,616a $28,674a,b
($43,394; $49,837) ($27,122; $30,226)
Regional $59,431a $45,288a,b
($56,603; $62,260) ($43,265; $47,311)
Distant $93,471a $62,868a,b
($83,203; $103,39) ($57,464; $68,271)
a
Excess cost is significantly different among breast cancer and comparison samples at the 1% level 95% confidence intervals in parentheses
bSignificantly different from women aged 18–44 years at the 1% level
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